Treatment of advanced breast cancer with cyclophosphamide, 5-fluorouracil, and prednisone with and without methanol-extracted residue of BCG

J. C. Britell, D. L. Ahmann, H. F. Bisel, S. Frytak, J. N. Ingle, J. Rubin, J. R. O'Fallon

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The value of immunotherapy as an adjuvant to chemotherapy for advanced breast cancer is an unsettled question. To clarify this issue, 71 women with measurable or evaluable metastatic breast cancer were randomized to receive cyclophosphamide, 5-fluorouracil, and prednisone (CFP) with or without methanol-extracted residue of Bacillus Calmette-Guerin (MER). The total regression rates were 52% (CFP) and 39% (CFP+MER), including complete regression rates of 13% (CFP) and 6% (CFP+MER). The median duration of regressions for CFP-treated patients was 257-261 days and for CFP + MER-treated patients was 385 days. The median time to progression was 248-261 days in the CFP group and 159 days in the CFP-MER group. Projected median survival for both treatment groups in 20 months. Immunotherapy (MER) as used in this study does not appear to augment regression rates or survival for patients with advanced breast cancer receiving CFP.

Original languageEnglish (US)
Pages (from-to)345-350
Number of pages6
JournalCancer Clinical Trials
Volume2
Issue number4
StatePublished - 1979
Externally publishedYes

Fingerprint

Mycobacterium bovis
Prednisone
Fluorouracil
Cyclophosphamide
Methanol
Breast Neoplasms
Therapeutics
Immunotherapy
Adjuvant Chemotherapy
Survival Rate
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Britell, J. C., Ahmann, D. L., Bisel, H. F., Frytak, S., Ingle, J. N., Rubin, J., & O'Fallon, J. R. (1979). Treatment of advanced breast cancer with cyclophosphamide, 5-fluorouracil, and prednisone with and without methanol-extracted residue of BCG. Cancer Clinical Trials, 2(4), 345-350.

Treatment of advanced breast cancer with cyclophosphamide, 5-fluorouracil, and prednisone with and without methanol-extracted residue of BCG. / Britell, J. C.; Ahmann, D. L.; Bisel, H. F.; Frytak, S.; Ingle, J. N.; Rubin, J.; O'Fallon, J. R.

In: Cancer Clinical Trials, Vol. 2, No. 4, 1979, p. 345-350.

Research output: Contribution to journalArticle

Britell, JC, Ahmann, DL, Bisel, HF, Frytak, S, Ingle, JN, Rubin, J & O'Fallon, JR 1979, 'Treatment of advanced breast cancer with cyclophosphamide, 5-fluorouracil, and prednisone with and without methanol-extracted residue of BCG', Cancer Clinical Trials, vol. 2, no. 4, pp. 345-350.
Britell, J. C. ; Ahmann, D. L. ; Bisel, H. F. ; Frytak, S. ; Ingle, J. N. ; Rubin, J. ; O'Fallon, J. R. / Treatment of advanced breast cancer with cyclophosphamide, 5-fluorouracil, and prednisone with and without methanol-extracted residue of BCG. In: Cancer Clinical Trials. 1979 ; Vol. 2, No. 4. pp. 345-350.
@article{bab106c2c6654e73840744c92e7883e1,
title = "Treatment of advanced breast cancer with cyclophosphamide, 5-fluorouracil, and prednisone with and without methanol-extracted residue of BCG",
abstract = "The value of immunotherapy as an adjuvant to chemotherapy for advanced breast cancer is an unsettled question. To clarify this issue, 71 women with measurable or evaluable metastatic breast cancer were randomized to receive cyclophosphamide, 5-fluorouracil, and prednisone (CFP) with or without methanol-extracted residue of Bacillus Calmette-Guerin (MER). The total regression rates were 52{\%} (CFP) and 39{\%} (CFP+MER), including complete regression rates of 13{\%} (CFP) and 6{\%} (CFP+MER). The median duration of regressions for CFP-treated patients was 257-261 days and for CFP + MER-treated patients was 385 days. The median time to progression was 248-261 days in the CFP group and 159 days in the CFP-MER group. Projected median survival for both treatment groups in 20 months. Immunotherapy (MER) as used in this study does not appear to augment regression rates or survival for patients with advanced breast cancer receiving CFP.",
author = "Britell, {J. C.} and Ahmann, {D. L.} and Bisel, {H. F.} and S. Frytak and Ingle, {J. N.} and J. Rubin and O'Fallon, {J. R.}",
year = "1979",
language = "English (US)",
volume = "2",
pages = "345--350",
journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Treatment of advanced breast cancer with cyclophosphamide, 5-fluorouracil, and prednisone with and without methanol-extracted residue of BCG

AU - Britell, J. C.

AU - Ahmann, D. L.

AU - Bisel, H. F.

AU - Frytak, S.

AU - Ingle, J. N.

AU - Rubin, J.

AU - O'Fallon, J. R.

PY - 1979

Y1 - 1979

N2 - The value of immunotherapy as an adjuvant to chemotherapy for advanced breast cancer is an unsettled question. To clarify this issue, 71 women with measurable or evaluable metastatic breast cancer were randomized to receive cyclophosphamide, 5-fluorouracil, and prednisone (CFP) with or without methanol-extracted residue of Bacillus Calmette-Guerin (MER). The total regression rates were 52% (CFP) and 39% (CFP+MER), including complete regression rates of 13% (CFP) and 6% (CFP+MER). The median duration of regressions for CFP-treated patients was 257-261 days and for CFP + MER-treated patients was 385 days. The median time to progression was 248-261 days in the CFP group and 159 days in the CFP-MER group. Projected median survival for both treatment groups in 20 months. Immunotherapy (MER) as used in this study does not appear to augment regression rates or survival for patients with advanced breast cancer receiving CFP.

AB - The value of immunotherapy as an adjuvant to chemotherapy for advanced breast cancer is an unsettled question. To clarify this issue, 71 women with measurable or evaluable metastatic breast cancer were randomized to receive cyclophosphamide, 5-fluorouracil, and prednisone (CFP) with or without methanol-extracted residue of Bacillus Calmette-Guerin (MER). The total regression rates were 52% (CFP) and 39% (CFP+MER), including complete regression rates of 13% (CFP) and 6% (CFP+MER). The median duration of regressions for CFP-treated patients was 257-261 days and for CFP + MER-treated patients was 385 days. The median time to progression was 248-261 days in the CFP group and 159 days in the CFP-MER group. Projected median survival for both treatment groups in 20 months. Immunotherapy (MER) as used in this study does not appear to augment regression rates or survival for patients with advanced breast cancer receiving CFP.

UR - http://www.scopus.com/inward/record.url?scp=0018768740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018768740&partnerID=8YFLogxK

M3 - Article

C2 - 394870

AN - SCOPUS:0018768740

VL - 2

SP - 345

EP - 350

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

SN - 0277-3732

IS - 4

ER -